Systemic Endocrine Instigation of Indolent Tumor Growth Requires Osteopontin

Cell

Volumn 133, Issue 6, 2008, Pages 994-1005

  McAllister, Sandra S ^a   Gifford, Ann M ^a   Greiner, Ashley L ^a,b   Kelleher, Stephen P ^a,c   Saelzler, Matthew P ^a,d   Ince, Tan A ^a,e   Reinhardt, Ferenc ^a   Harris, Lyndsay N ^f   Hylander, Bonnie L ^g   Repasky, Elizabeth A ^g   Weinberg, Robert A ^a,d  

^a WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

^b Boston University   (United States)

^c WILLIAMS COLLEGE   (United States)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f YALE UNIVERSITY MEDICAL CENTER   (United States)

^g ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

CELLCYCLE

Indexed keywords

OSTEOPONTIN;

ARTICLE; BREAST CARCINOMA; COLON CANCER; ENDOCRINE FUNCTION; HEMATOPOIETIC CELL; HOST; HUMAN; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; STEM CELL; STROMA; TUMOR CELL; TUMOR GROWTH;

EID: 44649088833     PISSN: 00928674     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cell.2008.04.045     Document Type: Article

References (45)

1. Bhowmick N.A., Neilson E.G., and Moses H.L. Stromal fibroblasts in cancer initiation and progression. Nature 432 (2004) 332-337
2. Cook A.C., Tuck A.B., McCarthy S., Turner J.G., Irby R.B., Bloom G.C., Yeatman T.J., and Chambers A.F. Osteopontin induces multiple changes in gene expression that reflect the six "hallmarks of cancer" in a model of breast cancer progression. Mol. Carcinog. 43 (2005) 225-236
3. Direkze N.C., and Alison M.R. Bone marrow and tumour stroma: an intimate relationship. Hematol. Oncol. 24 (2006) 189-195
4. Elenbaas B., Spirio L., Koerner F., Fleming M.D., Zimonjic D.B., Donaher J.L., Popescu N.C., Hahn W.C., and Weinberg R.A. Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev. 15 (2001) 50-65
5. Feng F., and Rittling S.R. Mammary tumor development in MMTV-c-myc/MMTV-v-Ha-ras transgenic mice is unaffected by osteopontin deficiency. Breast Cancer Res. Treat. 63 (2000) 71-79
6. Furger K.A., Menon R.K., Tuck A.B., Bramwell V.H., and Chambers A.F. The functional and clinical roles of osteopontin in cancer and metastasis. Curr. Mol. Med. 1 (2001) 621-632
7. Gohongi T., Fukumura D., Boucher Y., Yun C.O., Soff G.A., Compton C., Todoroki T., and Jain R.K. Tumor-host interactions in the gallbladder suppress distal angiogenesis and tumor growth: involvement of transforming growth factor beta1. Nat. Med. 5 (1999) 1203-1208
8. Graudens E., Boulanger V., Mollard C., Mariage-Samson R., Barlet X., Gremy G., Couillault C., Lajemi M., Piatier-Tonneau D., Zaborski P., et al. Deciphering cellular states of innate tumor drug responses. Genome Biol. 7 (2006) R19
9. Hahn W.C., Counter C.M., Lundberg A.S., Beijersbergen R.L., Brooks M.W., and Weinberg R.A. Creation of human tumour cells with defined genetic elements. Nature 400 (1999) 464-468
10. Hiratsuka S., Nakamura K., Iwai S., Murakami M., Itoh T., Kijima H., Shipley J.M., Senior R.M., and Shibuya M. MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell 2 (2002) 289-300
11. Hiratsuka S., Watanabe A., Aburatani H., and Maru Y. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat. Cell Biol. 8 (2006) 1369-1375
12. Hylander B.L., Pitoniak R., Penetrante R.B., Gibbs J.F., Oktay D., Cheng J., and Repasky E.A. The anti-tumor effect of Apo2L/TRAIL on patient pancreatic adenocarcinomas grown as xenografts in SCID mice. J. Transl. Med. 3 (2005) 22
13. Ince T.A., Richardson A.L., Bell G.W., Saitoh M., Godar S., Karnoub A.E., Iglehart J.D., and Weinberg R.A. Transformation of different human breast epithelial cell types leads to distinct tumor phenotypes. Cancer Cell 12 (2007) 160-170
14. Iwata M., Awaya N., Graf L., Kahl C., and Torok-Storb B. Human marrow stromal cells activate monocytes to secrete osteopontin, which down-regulates Notch1 gene expression in CD34+ cells. Blood 103 (2004) 4496-4502
15. Kaplan R.N., Riba R.D., Zacharoulis S., Bramley A.H., Vincent L., Costa C., MacDonald D.D., Jin D.K., Shido K., Kerns S.A., et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438 (2005) 820-827
16. Klarman K., Ortiz M., Davies M., and Keller J.R. Identification of in vitro growth conditions for c-Kit-negative hematopoietic stem cells. Blood 102 (2003) 3120-3128
17. Kondo M., Wagers A.J., Manz M.G., Prohaska S.S., Scherer D.C., Beilhack G.F., Shizuru J.A., and Weissman I.L. Biology of hematopoietic stem cells and progenitors: implications for clinical application. Annu. Rev. Immunol. 21 (2003) 759-806
18. Kopp H.G., Ramos C.A., and Rafii S. Contribution of endothelial progenitors and proangiogenic hematopoietic cells to vascularization of tumor and ischemic tissue. Curr. Opin. Hematol. 13 (2006) 175-181
19. Lamagna C., and Bergers G. The bone marrow constitutes a reservoir of pericyte progenitors. J. Leukoc. Biol. 80 (2006) 677-681
20. Minn A.J., Gupta G.P., Siegel P.M., Bos P.D., Shu W., Giri D.D., Viale A., Olshen A.B., Gerald W.L., and Massague J. Genes that mediate breast cancer metastasis to lung. Nature 436 (2005) 518-524
21. Mor G., Visintin I., Lai Y., Zhao H., Schwartz P., Rutherford T., Yue L., Bray-Ward P., and Ward D.C. Serum protein markers for early detection of ovarian cancer. Proc. Natl. Acad. Sci. USA 102 (2005) 7677-7682
22. Naka T., Sugamura K., Hylander B.L., Widmer M.B., Rustum Y.M., and Repasky E.A. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice. Cancer Res. 62 (2002) 5800-5806
23. Nilsson S.K., Johnston H.M., Whitty G.A., Williams B., Webb R.J., Denhardt D.T., Bertoncello I., Bendall L.J., Simmons P.J., and Haylock D.N. Osteopontin, a key component of the hematopoietic stem cell niche and regulator of primitive hematopoietic progenitor cells. Blood 106 (2005) 1232-1239
24. O'Reilly M.S., Holmgren L., Shing Y., Chen C., Rosenthal R.A., Moses M., Lane W.S., Cao Y., Sage E.H., and Folkman J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79 (1994) 315-328
25. O'Reilly M.S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W.S., Flynn E., Birkhead J.R., Olsen B.R., and Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88 (1997) 277-285
26. Oft M., Peli J., Rudaz C., Schwarz H., Beug H., and Reichmann E. TGF-beta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes Dev. 10 (1996) 2462-2477
27. Olumi A.F., Grossfeld G.D., Hayward S.W., Carroll P.R., Tlsty T.D., and Cunha G.R. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 59 (1999) 5002-5011
28. Orimo A., Gupta P.B., Sgroi D.C., Arenzana-Seisdedos F., Delaunay T., Naeem R., Carey V.J., Richardson A.L., and Weinberg R.A. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121 (2005) 335-348
29. Ramankulov A., Lein M., Kristiansen G., Meyer H.A., Loening S.A., and Jung K. Elevated plasma osteopontin as marker for distant metastases and poor survival in patients with renal cell carcinoma. J. Cancer Res. Clin. Oncol. 133 (2007) 643-652
30. Randall T.D., and Weissman I.L. Characterization of a population of cells in the bone marrow that phenotypically mimics hematopoietic stem cells: resting stem cells or mystery population?. Stem Cells 16 (1998) 38-48
31. Richardson A.L., Wang Z.C., De Nicolo A., Lu X., Brown M., Miron A., Liao X., Iglehart J.D., Livingston D.M., and Ganesan S. X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 9 (2006) 121-132
32. Rittling S.R., and Chambers A.F. Role of osteopontin in tumour progression. Br. J. Cancer 90 (2004) 1877-1881
33. Schmits R., Filmus J., Gerwin N., Senaldi G., Kiefer F., Kundig T., Wakeham A., Shahinian A., Catzavelos C., Rak J., et al. CD44 regulates hematopoietic progenitor distribution, granuloma formation, and tumorigenicity. Blood 90 (1997) 2217-2233
34. Scott L.M., Priestley G.V., and Papayannopoulou T. Deletion of alpha4 integrins from adult hematopoietic cells reveals roles in homeostasis, regeneration, and homing. Mol. Cell. Biol. 23 (2003) 9349-9360
35. Sendobry S.M., Cornicelli J.A., Welch K., Bocan T., Tait B., Trivedi B.K., Colbry N., Dyer R.D., Feinmark S.J., and Daugherty A. Attenuation of diet-induced atherosclerosis in rabbits with a highly selective 15-lipoxygenase inhibitor lacking significant antioxidant properties. Br. J. Pharmacol. 120 (1997) 1199-1206
36. Shojaei F., Wu X., Malik A.K., Zhong C., Baldwin M.E., Schanz S., Fuh G., Gerber H.P., and Ferrara N. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat. Biotechnol. 25 (2007) 911-920
37. Song S., Ewald A.J., Stallcup W., Werb Z., and Bergers G. PDGFRbeta+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nat. Cell Biol. 7 (2005) 870-879
38. Stewart S.A., Dykxhoorn D.M., Palliser D., Mizuno H., Yu E.Y., An D.S., Sabatini D.M., Chen I.S., Hahn W.C., Sharp P.A., et al. Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA 9 (2003) 493-501
39. Stier S., Ko Y., Forkert R., Lutz C., Neuhaus T., Grunewald E., Cheng T., Dombkowski D., Calvi L.M., Rittling S.R., and Scadden D.T. Osteopontin is a hematopoietic stem cell niche component that negatively regulates stem cell pool size. J. Exp. Med. 201 (2005) 1781-1791
40. Tlsty T.D., and Coussens L.M. Tumor stroma and regulation of cancer development. Annu. Rev. Pathol. 1 (2006) 119-150
41. Tuck A.B., Chambers A.F., and Allan A.L. Osteopontin overexpression in breast cancer: knowledge gained and possible implications for clinical management. J. Cell Biol. 102 (2007) 859-868
42. Udagawa T., Puder M., Wood M., Schaefer B.C., and D'Amato R.J. Analysis of tumor-associated stromal cells using SCID GFP transgenic mice: contribution of local and bone marrow-derived host cells. FASEB J. 20 (2006) 95-102
43. van de Vijver M.J., He Y.D., van't Veer L.J., Dai H., Hart A.A., Voskuil D.W., Schreiber G.J., Peterse J.L., Roberts C., Marton M.J., et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347 (2002) 1999-2009
44. Wai P.Y., Mi Z., Guo H., Sarraf-Yazdi S., Gao C., Wei J., Marroquin C.E., Clary B., and Kuo P.C. Osteopontin silencing by small interfering RNA suppresses in vitro and in vivo CT26 murine colon adenocarcinoma metastasis. Carcinogenesis 26 (2005) 741-751
45. Yang L., Huang J., Ren X., Gorska A.E., Chytil A., Aakre M., Carbone D.P., Matrisian L.M., Richmond A., Lin P.C., and Moses H.L. Abrogation of TGFb signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 13 (2008) 23-35